In an interview with Dean M. Eric Johnson, Illumina CFO Sam Samad discusses how DNA sequencing moves the delivery of health care from a disease-centered model toward a patient-centered one.He describes how Illumina has dramatically driven down the cost of sequences and what that means for patients. He shares a leadership lesson on the difference between mentoring and championing as well. Sam is the CFO of Illumina - a California-based company and leader in the market for DNA-sequencing equipment.